Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.206
+0.008 (4.10%)
At close: Feb 21, 2025, 4:00 PM
0.202
-0.004 (-2.04%)
After-hours: Feb 21, 2025, 6:03 PM EST
Lyra Therapeutics Employees
Lyra Therapeutics had 88 employees as of December 31, 2023. The number of employees increased by 30 or 51.72% compared to the previous year.
Employees
88
Change (1Y)
30
Growth (1Y)
51.72%
Revenue / Employee
$16,716
Profits / Employee
-$1,109,227
Market Cap
13.46M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 30 | 51.72% |
Dec 31, 2022 | 58 | 5 | 9.43% |
Dec 31, 2021 | 53 | 15 | 39.47% |
Dec 31, 2020 | 38 | 0 | - |
Dec 31, 2019 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
LYRA News
- 3 months ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 5 months ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 10 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 10 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - 3 'Buy-Rated' Biotech Stocks Under $10 - Seeking Alpha